Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: NIMBEX

Summary for Tradename: NIMBEX

Suppliers: see list1
patent expirations by year for

Pharmacology for Tradename: NIMBEX

Clinical Trials for: NIMBEX

Study of Cisatracurium and Sufentanil Consumption Using a Closed Loop Computer Control Infusion System
Status: Recruiting Condition: The Intraoperative Effect of Dexmedetomidine on Cisatracurium Infusion Consumption and Its Recovery Index.; Effect of Dexmedetomidine on Sufentanil Consumption.; Quantitative Analysis of Cisatracurium Infusion Requirements, Sufentanil Consumption and Recovery Index in Different Age Groups.

Effect of Laparoscopic Operation on Rocuronium and Cisatracurium: Pharmacokinetic and Pharmacodynamic Analysis
Status: Not yet recruiting Condition: C.Delivery; Surgery (Previous), Gynecological

Comparison Between Cisatracurium and Rocuronium in Terms of Recovery of the Muscular Strength in the Postoperative Phase After Surgery and General Anaesthesia
Status: Completed Condition: Postoperative Residual Curarization; Residual Neuromuscular Block

Comparison of the Effects of Vecuronium and Cisatracurium on Electrophysiologic Monitoring During Neurosurgery
Status: Completed Condition: Motor Evoked Potential Monitoring; General Anesthesia; Neurosurgery; Brain Tumor; Spine Tumor; Cerebral Aneurysm

When Cooling a Patient After Cardiac Arrest, Does Use of a Neuromuscular Blocking Agent Make Your Job Easier?
Status: Not yet recruiting Condition: Postcardiac Arrest Therapeutic Hypothermia

Effect of Cisatracurium Versus Atracurium on Intraocular Pressure in Patients Underwent General Anesthesia
Status: Completed Condition: Intraocular Pressure

Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium
Status: Completed Condition: Observation of Neuromuscular Block

Analysis of Cisatracurium Consumption in Balanced Anesthesia With 1% Sevoflurane, and With Only Sevoflurane, Using a Closed-loop Computer Controlled System Infusion.
Status: Completed Condition: Drug Interaction Potentiation

A Study of Residual Curarization Incidence in China
Status: Recruiting Condition: Perioperative/Postoperative Complications; PORC (Postoperative Residual Curarization)

Effect of Nitrous Oxide on Cisatracurium Infusion Demands
Status: Completed Condition: Neuromuscular Blocking Agents

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
cisatracurium besylate
INJECTABLE;INJECTION020551Dec 15, 1995RXYes<disabled><disabled>
cisatracurium besylate
INJECTABLE;INJECTION020551Dec 15, 1995RXYes<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: NIMBEX

Drugname Dosage Strength RLD Submissiondate
cisatracurium besylate (preserve free)Injection2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vialNimbex8/4/2009
cisatracurium besylate (multi-dose)     Injection2 mg/mL, 10 mL vialNimbex8/12/2009

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology